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Efficacy of baricitinib in the treatment of chilblains 
associated with Aicardi- Goutières syndrome, a type I 
interferonopathy
Aicardi- Goutières syndrome (AGS) is a rare, juvenile- onset 
autoinflammatory disease characterized by basal ganglia calcifi-
cation, chronic cerebrospinal fluid (CSF) lymphocytosis, and ele-
vated type I interferon (IFN) levels in the CSF (1,2). Typical clinical 
manifestations include developmental delay, intellectual impair-
ment, chilblains, panniculitis, glaucoma, and autoimmunity over-
lapping with systemic lupus erythematosus (SLE) (1,3).
AGS is classified as a monogenic type I interferonopathy 
with autoinflammation resulting from constitutive up- regulation of 
type I IFN signaling (3). IFN- stimulated genes (ISGs) are constantly 
overexpressed in peripheral blood cells from AGS patients, and 
measurement of ISGs in these cells is a useful marker for dis-
ease activity (4,5). At least 7 distinct gene mutations have been 
reported for AGS, including mutations in SAMHD1 (1). SAMHD1 
loss- of- function mutations are associated with dysfunctional cyto-
solic dNTP metabolism and overproduction of type I IFNs (1).
JAK/STAT activation is present in various autoimmune 
diseases, and treatment with specific JAK inhibitors in 
immune-mediated diseases has been increasingly reported 
(6). Recently, the oral JAK1/2 inhibitor baricitinib was approved 
for the treatment of active rheumatoid arthritis and was also 
found to be effective in the treatment of a patient with a STAT1 
gain- of- function mutation (7). In this report, we describe 
an AGS patient treated with baricitinib and demonstrate 
its potential clinical applications for the treatment of type I 
 interferonopathies.
The patient, a 22- year- old Caucasian woman with a con-
sanguineous family history, was diagnosed as having AGS at age 
19 years based on a homozygous nonsense mutation in exon 4 
of SAMHD1 (c.490C>T [p.Arg164Ter]). This mutation has been 
described previously in AGS (8). Her medical history included 
subclinical hypothyroidism, basal ganglia calcifications, and mild 
intellectual disability. The most prominent clinical feature was 
severe chilblains, which had been active over many years. Scaly 
and crusted ulcers from chilblains persisted on both hands and 
feet (Figure 1A). Inflammation and pain were typically exacerbated 
after cold exposure.
Baricitinib treatment was initiated at a daily dose of 2 mg/
kg. At the start of baricitinib therapy, the patient experienced 
active chilblains of the hands and feet. After 6 weeks of treat-
ment, the lesions completely resolved. To date, there has been 
no recurrence of chilblains after 18 months of treatment (Fig-
ure 1A). Lesions also did not reappear during winter, when the 
disease was usually more active. No occurrences of viral infec-
tions, opportunistic infections, or other complications were 
reported during treatment.
Peripheral blood samples were collected from the patient 
4 weeks prior to the start of baricitinib therapy and after 2 
and 6 weeks of treatment. Expression levels of 5 ISGs (IFI44, 
IFI44L, IFIT3, LY6E, and MX1) representing the gene signature 
for type I IFN activity (9) were measured in isolated CD14+ 
monocytes by quantitative reverse transcription–polymerase 
chain reaction and compared to the expression levels in 54 
healthy controls. Prior to baricitinib therapy, monocytes from 
the patient displayed higher expression of all tested ISGs 
compared to healthy controls (Figure 1B). Expression of all 5 
ISGs declined remarkably after initiation of baricitinib treatment 
 (Figure 1B).
Furthermore, we measured total STAT1 and phos-
phorylated  STAT1 in peripheral blood T lymphocytes by flow 
cytometry (7). Before and during treatment, T lymphocytes from 
the patient expressed higher levels of total STAT1 than those 
observed in 2 age- , sex- , and race- matched healthy controls 
(Figure 1C). As shown in Figures 1D and E, T lymphocytes from 
the patient before and during baricitinib therapy displayed base-
line levels of phosphorylated STAT1 comparable to those in the 
healthy controls. However, T lymphocytes obtained from the 
patient before treatment displayed much higher levels of phos-
phorylated STAT1 upon IFNα stimulation than healthy control 
T lymphocytes. The enhanced level of phosphorylated STAT1 
observed in patient T lymphocytes before baricitinib treatment 
was strongly reduced during treatment.
In summary, our findings suggest that baricitinib is a novel 
drug for the treatment of chilblains in AGS patients with a SAMHD1 
mutation and consequent up- regulation of type I IFN activity. The 
immunologic effects of JAK inhibitors depend on their selectivity 
and inhibitory capacity for the several JAK subtypes. Baricitinib 
displays a stronger inhibitory effect on cytokine- induced phos-
phorylated STAT1 than ruxolitinib, which had been previously 
reported as successful in the treatment of STING- associated 
type I interferonopathy (6,10). Therefore, more in- depth research 
is warranted to evaluate baricitinib in the treatment of type I 
 interferonopathies.
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Figure 1. Clinical and immunologic response to baricitinib (BRN) treatment in a patient with Aicardi- Goutières syndrome (AGS). A, Dermatologic 
manifestations in the hands and feet before treatment (left), and clinical improvement during the fifth month of therapy (right). B, Expression of 
mRNA for interferon (IFN)–stimulated genes (ISGs) in monocytes from healthy controls (left) and from the patient before and during the treatment 
(right). Data were normalized to the housekeeping gene ABL. Data in the left panel are shown as box plots. Each box represents the 25th 
to 75th percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th percentiles. C, Total 
STAT1 levels in T lymphocytes from the patient and healthy controls. D, Phosphorylated STAT1 levels in T lymphocytes upon IFNα induction. 
E, Kinetics of phosphorylated STAT1 levels in T lymphocytes upon stimulation with IFNα for the indicated time periods. Values in C and E are 
the mean ± SEM. MFI = mean fluorescence intensity; US = unstimulated.
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Clinical Images: Heel pain in a young patient—calcaneal involvement in juvenile spondyloarthritis
The patient, an 11- year- old boy, presented with left heel pain and mild fever. He had recently experienced diffuse arthralgias of the right knee, 
costochondral junctions, and both ankles. Laboratory findings were normal except for a slightly increased erythrocyte sedimentation rate. 
Magnetic resonance imaging (MRI) of the left heel was performed. On T1- weighted and fat- suppressed T2- weighted MRI sequences, bone 
marrow edema with indistinct margins was seen at the posterior margin of the calcaneus, above the growth plate, and below its posterior 
and superior cortex (A and B) (arrows). The shape of the apophysis was preserved. Enhancement was seen in the area of the bone marrow 
edema after gadolinium injection (C) (arrow), and the calcaneal bursa was also enhanced. This pattern of marrow changes differed from the 
thin high- signal- intensity strip normally seen along the growth plate at this age and from the normal variant of scattered patchy areas some-
times present in the posterior calcaneus (D and E) (arrows) (1). Sever’s disease was ruled out as it mainly affects the secondary ossification 
center. Spondyloarthritis was diagnosed based on the calcaneal bone marrow edema and the involvement of the adjacent soft tissues below 
the Achilles tendon in a clinical context of diffuse arthralgias. This case illustrates calcaneal involvement in juvenile spondyloarthritis, which 
consisted of bone marrow edema and gadolinium enhancement involving the superior area of the posterior calcaneus above the secondary 
ossification center as well as the calcaneal bursa. Interestingly, in this patient, bone marrow changes predominated in the superior part of the 
posterior calcaneus at the level of the periosteal fibrocartilage located above the secondary ossification center and the Achilles enthesis (2).
Stacey Lallemand, MD  
Jean-Denis Laredo, MD, MS
Lariboisière Hospital 
Paris, France
A B C D E
 1. Rossi I, Rosenberg Z, Zember J. Normal skeletal development and 
imaging pitfalls of the calcaneal apophysis: MRI features. Skeletal Ra-
diol 2016;45:483–93.
 2. Benjamin M, McGonagle D. The anatomical basis for disease locali-
sation in seronegative spondyloarthropathy at entheses and related 
sites. J Anat 2001;199:503–26.
